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Abstract 
Background: Endothelial dysfunction is an early marker of cardiovascular disease so endothelial and arterial stiffness 
indexes are good indicators of vascular health. We aimed to assess whether the presence of diabetic foot is associated 
with arterial stiffness and endothelial function impairment.
Methods: We studied 50 subjects with type 2 diabetes mellitus and diabetic foot syndrome (DFS) compared to 50 
diabetic subjects without diabetic foot, and 53 patients without diabetes mellitus, by means of the mini mental state 
examination (MMSE) administered to evaluate cognitive performance. Carotid-femoral pulse wave velocity (PWV) and 
augmentation index (Aix) were also evaluated by Applanation tonometry (SphygmoCor version 7.1), and the RH-PAT 
data were digitally analyzed online by Endo-PAT2000 using reactive hyperemia index (RHI) values.
Results: In comparison to diabetic subjects without diabetic foot the subjects with diabetic foot had higher mean 
values of PWV, lower mean values of RHI, and lower mean MMSE. At multinomial logistic regression PWV and RHI were 
significantly associated with diabetic foot presence, whereas ROC curve analysis had good sensitivity and specificity in 
arterial PWV and RHI for diabetic foot presence.
Conclusions: Pulse wave velocity and augmentation index, mean RHI values, and mean MMSE were effective indica-
tors of diabetic foot. Future research could address these issues by means of longitudinal studies to evaluate cardio-
vascular event incidence in relation to arterial stiffness, endothelial and cognitive markers.
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Background
Diabetic foot syndrome (DFS) or disease (DFD) includes 
several pathologies, mainly diabetic peripheral neuropa-
thy and peripheral arterial disease which result in foot 
ulceration [1, 2].
Recent studies [3–5] have highlighted the association 
between the occurrence of diabetic foot ulcer and micro-
angiopathy complications, including albuminuria (Alb) 
and diabetic retinopathy (DR), thus underlying the patho-
genic role of vascular disease in DFS pathogenesis [5–11]. 
Understanding of the pathophysiology of atherosclerosis 
and its vascular complications has increased dramati-
cally, developing numerous measurable biomarkers that 
play a role in the atherosclerosis process, and are asso-
ciated with clinically important vascular events. Puta-
tive measurable variables include soluble biomarkers and 
imaging assessments of vascular structure and function.
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Our group reported [12] that compared to diabet-
ics without diabetic foot, diabetic subjects with diabetic 
foot had higher IL-6 and resistin plasma levels, and lower 
adiponectin plasma levels, as possible determinants of 
higher cardiovascular risk. Endothelial dysfunction is an 
early marker of vascular diseases, and methods of assess-
ing endothelial function and arterial stiffness are available 
for clinical research confirming that endothelial function 
and arterial stiffness markers are surrogate cardiovascu-
lar markers [13].
Endothelial dysfunction in peripheral arteries is 
assessed by forearm flow-mediated vasodilation [13]. 
However, the results of forearm flow-mediated vasodi-
lation can vary due to technical problems encountered 
during measurement, and thus forearm flow-mediated 
vasodilation is not standardized among institutions 
[14]. Kuvin et al. [15] described a new method to evalu-
ate endothelial dysfunction called reactive hyperemia 
peripheral arterial tonometry (RH-PAT). It is a noninva-
sive, automatic, and quantitative clinical test for digital 
measurement of hyperemic response, and inversely cor-
relates with various cardiovascular risk factors [16] indi-
cating the practical usefulness of the RH-PAT test.
Considering the reported link between diabetic foot 
and cardiovascular risk and consistent with the role of 
putative cardiovascular surrogate markers of arterial stiff-
ness and endothelial function indexes, we aimed to assess 
whether the presence of diabetic foot is associated with 
arterial stiffness and endothelial function index impair-
ment in a group of patients with diabetic foot syndrome 
compared to age matched diabetic subjects without foot 
complications and age-matched healthy subjects.
Methods
We recruited all subjects with type 2 diabetes mellitus 
and foot ulceration referred to the Diabetic Foot Inter-
vention Clinical Group of Policlinico “P. Giaccone” Hos-
pital of the University of Palermo, Italy from September 
2014 to December 2015; we also recruited diabetic sub-
jects without diabetic foot admitted from September 
2014 to December 2015 for every condition related to 
diabetic disease (decompensated diabetes, hypoglyce-
mia, but not for new vascular events) in the U.O.C di 
Medicina Interna con Stroke Care of University Poli-
clinico “P. Giaccone” Hospital of Palermo, and consecu-
tive patients without diabetes mellitus admitted to our 
wards for causes other than diabetic foot and acute car-
diovascular events between 2013 and 2015. The study 
was carried out in accordance with the principles of the 
Declaration of Helsinki as revised in 2001. All patients 
gave informed consent to take part in this research. We 
obtained consent for publication from the participant (or 
legal parent) to report individual patient data.
Diabetic foot syndrome is defined, according to the 
World Health Organization, as “ulceration of the foot 
(distally from the ankle and including the ankle) associ-
ated with neuropathy and different grades of ischemia 
and infection [17]. Foot ulcer was defined as a full-thick-
ness skin defect that required ≥14 days for healing [18]. 
Every subject with diabetic foot was matched for age 
(±3 years) and sex, with one subject without diabetic foot 
and one healthy subject.
Patients with inflammatory or infectious diseases, 
autoimmune and rheumatic diseases, cancer, hemato-
logical diseases and severe renal or liver failure, as well as 
those who were under treatment with anti-inflammatory 
drugs, were excluded. We also excluded patients with 
fever and recent venous thromboembolism. A physi-
cal examination with emphasis on the lower limbs was 
performed by researchers, who assessed the presence of 
the following characteristics: hammer/claw toe, Charcot 
deformity, hallux limitus, prominent metatarsal heads, 
hallux valgus, bony prominences, and ankle and halluxo-
bility measured by goniometry.
Diabetic peripheral neuropathy was evaluated by care-
ful patient history review and physical examination of 
the feet using the combination of patient’s neuropathic 
symptoms, clinical signs and diagnostic tests. To assess 
the neuropathic symptoms we used the Neuropathy 
Symptom Score (NSS) [19], which is widely used in clini-
cal practice and has shown high validity and sensitivity. 
Semmes–Weinstein monofilament was the tool used for 
the assessment of the diabetic peripheral neuropath [20]. 
Diagnosis of type 2 diabetes was based on the revised cri-
teria of the American Diabetes Association, using a value 
of fasting blood glucose  ≥126  mg/dl, or it was deter-
mined using a clinically based algorithm that considered 
age at onset, presenting weight and symptoms, family 
history, onset of insulin treatment, and history of ketoac-
idosis [21]. Hypertension was defined according to the 
2013 ESC–ESH criteria [22]. Dyslipidemia was defined 
as TG level ≥150  mg/dl and LDL cholesterol  >100  mg/
dl and HDL cholesterol level  <40  mg/dl (regardless of 
patient’s gender) [23].
Clinical and laboratory assessment
Clinical and anthropometric data were collected at 
the time of enrollment. Subjects were classified as nor-
mal weight (BMI 18.5–24.9  kg/m2), overweight (BMI 
25–29.9), or obese (BMI ≥30). A 12-h overnight fasting 
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blood sample was drawn at the time of enrollment to 
determine the serum levels of ALT, total cholesterol, 
HDL-cholesterol, triglycerides, and plasma glucose.
Assessment of cognitive function (mini mental state 
examination)
The mini mental state examination (MMSE)—a tool 
that can be used to systematically and thoroughly assess 
mental status—was administered. It is an 11-question 
measure that tests 5 areas of cognitive function (orien-
tation, registration, attention and calculation, recall, and 
language). The maximum score is 30 whereas a MMSE 
value <24 (23 or lower) is indicative of cognitive impair-
ment [24].
PWV measurement
Carotid-femoral PWV was measured in the supine posi-
tion using the automatic device (SphygmoCor version 
7.1) that measured the time delay between the rapid 
upstroke of the carotid and femoral artery pulse waves. 
The distance between the 2 arterial points was measured 
on the surface of the body using a tape measure. PWV 
was calculated as the distance traveled by the arterial 
pulse wave (in meters) divided by the time delay between 
the 2 arterial points (in seconds), thus expressed as 
meters per second.
Pulse wave analysis
Applanation tonometry was used to record radial artery 
pressure waveform continuously, and mean values of ≥2 
screens of pulse waves of good quality were used for anal-
ysis. On the basis of the collected data, an averaged radial 
pressure waveform was generated and a corresponding 
aortic pressure waveform and BP were calculated by the 
validated transfer function (SphygmoCor version 7.1). 
The aortic pressure waveform was used to calculate the 
AIx (difference in height between the first and second 
systolic peaks expressed as a percentage of PP).
Rh‑pat
The principle of RH-PAT has been described previ-
ously by researchers [16]. Briefly, a blood pressure cuff 
was placed on 1 upper arm, while the contralateral arm 
served as a control. PAT probes were placed on 1 finger 
of each hand. After a 5-min equilibration period, the cuff 
was inflated to 60 mm Hg above the systolic pressure or 
200 mm Hg for 5 min and then deflated to induce reac-
tive hyperemia. The RH-PAT data were digitally analyzed 
online (Endo-PAT2000 software version 3.0.4). The RH-
PAT index reflects the extent of reactive hyperemia and 
was calculated as the ratio of the average amplitude of 
PAT signal over 1 min starting 1.5 min after cuff deflation 
(control arm, A; occluded arm, C) divided by the average 
amplitude of the PAT signal of a 2.5-min time period 
before cuff inflation (baseline) (control arm, B; occluded 
arm, D). Thus RH-PAT index (RHI)  =  (C/D)/(A/B) × 
baseline correction.
Statistical analysis
Statistical analysis of quantitative and qualitative data, 
including descriptive statistics, was performed for all 
items. Continuous data are expressed as mean  ±  SD, 
unless otherwise specified. Baseline differences between 
groups were assessed by the Chi square test or Fisher 
exact test, as needed for categorical variables, and by the 
univariate analysis of variance (ANOVA) for paramet-
ric variables. Multinomial logistic regression analysis 
examined the correlation between patient characteristics 
(independent variables), and patient groups (depend-
ent variable) in a multiple regression model. Odds ratios 
(OR) and their 95% confidence intervals (CIs) were also 
calculated and adjusted for drug therapy as covariate. We 
also adjusted for other clinical variables such as BMI and 
BSA. To assess the predictive rate of different cutoff val-
ues of PWV, Aix and RHI values with regard to patient 
groups, a receiver operating characteristic (ROC) curve 
with calculations of area under the curve and 95% CI was 
constructed, and sensitivity and specificity values were 
calculated. Spearman correlation analysis was conducted 
to examine the association between RHI, arterial stiffness 
indexes, MMSE and other clinical and laboratory varia-
bles in patient groups. Data were analyzed by the Epi Info 
software (version 6.0, Centers for Disease Control and 
Prevention, Atlanta, GA, USA), and SPSS Software 22.0 
version (IBM Corp., Armonk, NY, USA). All P-values 
were two-sided, and P-values less than 0.05 were consid-
ered statistically significant.
Results
We enrolled 50 subjects with diabetic foot, 50 diabetic 
subjects without diabetic foot and 53 healthy subjects. 
General and laboratory variables of diabetic patients with 
diabetic foot and healthy subjects are listed in Table  1. 
In comparison to diabetic subjects without diabetic 
foot, patients with diabetic foot were more likely to have 
higher systolic blood pressure (135.0 ±  21.8  mm/Hg vs. 
124.5  ±  16.8 vs. 116.3  ±  13.4, P  <  0.0001), higher BMI 
(30.2 ± 6.4 vs. 29.9 ± 4.5 vs. 25.1 ± 4.3; P < 0.0001), higher 
frequency of hypertension (92 vs. 62 vs. 41%; P < 0.0001), 
higher frequency of previous cardiovascular events (24 vs. 
1 vs. 0%; P < 0.0001), and higher frequency of dyslipidae-
mia (70 vs. 44 vs. 15%; P < 0.0001) (see Table 1).
In comparison to diabetic subjects without diabetic 
foot and healthy subjects, the subjects with diabetic 
foot also had higher mean values of PWV (14.3  ±  3.8 
vs. 11.9  ±  2.6  vs. 9.2  ±  1.9  m/sec; P  <  0.0001), lower 
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mean value of RHI (1.6 ± 0.4 vs. 1.8 ± 0.5 vs. 2.4 ± 0.6; 
P  <  0.0001), lower mean value of MMSE (26.5  ±  3.6 
vs. 27.4  ±  2.26 vs. 29.2  ±  1.1; P  <  0.0001). No signifi-
cant difference was found between subjects with dia-
betic foot and diabetic subjects without diabetic foot 
(6.1 ± 1.3 years vs. 6.5 ± 2.2 years; P = 0.56).
At multinomial logistic regression analysis of variables 
independently associated with diabetes and diabetic foot 
presence, we found that age (OR: 1.06; P = 0.030), BMI 
(OR: 1.21; P = 0.002), PWV (OR: 1.60; P = 0.014), RHI 
(OR: 0.31; P = 0.043) and MMSE (OR: 0.17; P = 0.036) 
were associated with diabetes, whereas hypertension 
(OR: 21.3; P < 0.0001), Dyslipidaemia (OR: 6.1; P < 0.014), 
BMI (OR: 1.2; P =  0.019), PWV (OR: 2.26; P =  0.002), 
RHI (OR: 0.011; p = 0.002) (see Table 2) were associated 
with diabetic foot presence.
Moreover by means of ROC curve analysis there 
was good sensitivity and specificity of arterial PWV 
Table 1 Demographic, clinical and laboratory variables in subjects with diabetic foot and in controls (diabetic subjects 
without diabetic foot and subjects without diabetes)
BMI body mass index, BSA body surface area, SBP systolic blood pressure, DBP diastolic blood pressure, Aortic AIx aortic augmentation index, AP augmentation 
pressure, PWV pulse wave velocity, RHI reactive hyperaemia index, MMSE mini mental state examination, HbA1c glycated haemoglobin, ARBs angiotensin receptor 1 
blockers, eGFR estimated glomerular filtration rate according Cockcroft and Gault formula, CCB calcium channel blockers
Italic values indicate significance of p value (p < 0.05)
Subjects with diabetic  
foot
(n: 50)
Diabetic subjects  
without  
diabetic foot
(n: 50)
Healthy controls
(n: 53)
p
M/F (n/%) 35/15 (70/30) 27/23 (54/46) 26/27 (49.1/50.9) 0.087
Age (years) (mean ± SD) 61.6 ± 10.1 60.6 ± 12.5 63.0 ± 13.9 0.71
SBP (mm/hg)
(mean ± SD)
135.0 ± 21.8 124.5 ± 16.8 116.3 ± 13.4 <0.0001
DBP (mm/hg) (mean ± SD) 67.9 ± 10.7 70.9 ± 11.2 71.3 ± 12.7 0.283
BMI (kg/m2)
(mean ± SD)
30.2 ± 6.4 29.9 ± 4.5 25.1 ± 4.3 <0.0001
BSA
(mean ± SD)
2.02 ± 0.23 1.97 ± 0.25 1.79 ± 0.23 <0.0001
Creatinin (mg/dl) (mean ± SD) 1.05–0.27 1.01 ± 0.27 0.90 ± 0.11 0.008
EGFR (ml/min) (mean ± SD) 73.46 ± 13.48 73.38 ± 13.53 92.59 ± 6.06 <0.0001
Micro albuminuria (n/ %) 12 14 0 <0.0001
Hypertension (n/%) 46 (92) 31 (62) 5 (9) <0.0001
Previous cardiovascular events (n/%) 12 (24) 5 (1) 0 (0) <0.0001
Previous stroke
(n/%)
3 (6) 2 (4) 0 (0) 0.202
Dyslipidaemia
(n/%)
35 (70) 22 (44) 8 (15.1) <0.0001
AIX (%)
(mean ± SD)
139.1 ± 19.2/27.3 ± 9.8 145.0 ± 27.5/29.0 ± 12.1 130.8 ± 34.8/22.3 ± 14.8 0.039
PWV (m/sec)
(mean ± SD)
14.3 ± 3.8 11.9 ± 2.6 9.2 ± 1.9 <0.0001
RHI (mean ± SD) 1.6 ± 0.4 1.8 ± 0.5 2.4 ± 0.6 <0.0001
MMSE (mean/sd) 26.5 ± 3.6 27.42 ± 2.3 29.2 ± 1.1 <0.0001
(HbA1c) (%)
(mean/sd)
8.2 ± 1.3 7.3 ± 1.1 – <0.0001
Antihypertensive drugs (%/n)
 Ace-inhibitors (26/52) 23 (46) 0 <0.0001
 ARBs 13 (26) 10 (20) 0 <0.0001
 (CCB) 10 (20) 9 (18) 0 <0.0001
Statins (%/n) 29 (58) 28 (56) 0 <0.0001
Antidiabetic drugs (%/n)
 Sulfonylureas 23 (46) 21 (42) 0 <0.0001
 Metformin 22 (44) 23 (46) 0 <0.0001
 Insulin 38 (76) 31 (62) 0 <0.0001
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(AUC = 0.816, P < 0.0001; cutoff value ≥9.4 m/sec, sen-
sitivity = 90, specificity = 60.4) and RHI (AUC = 0.751, 
P  <  0.0001; cutoff value ≤  2.05, sensitivity =  78, speci-
ficity = 64.2) for diabetes presence compared to healthy 
subjects (see Fig. 1).
On ROC curve analysis there was also good sensitivity 
and specificity of arterial PWV (AUC = 0.897, P < 0.0001; 
cutoff value ≥  10.1, sensitivity =  90, specificity =  75.5) 
and RHI (AUC =  0.869, P < 0.0001; cutoff value ≤1.72, 
sensitivity  =  72, specificity  =  84.9) for diabetic foot 
presence compared to healthy subjects, and PWV 
(AUC = 0.690, P = 0.003; cutoff value ≥ 14.5 m/sec, sen-
sitivity =  50, specificity =  92) and RHI (AUC =  0.654, 
P =  0.0049; cutoff value ≤  1.45 m/sec, sensitivity =  48, 
specificity = 80) predicted diabetic foot compared to dia-
betic subjects (see Fig. 1).
In subjects with diabetic foot on correlation analysis we 
observed a significant negative correlation between PWV 
and RHI (r  =  −0.31, P  =  0.029), a significant negative 
correlation between RHI and previous cardiovascular 
events (r = −0.30, P = 0.029) and glycated hemoglobin 
(HbA1c) (r = −0.30; P = 0.030), and between MMSE and 
age (r  =  −0.50, P  <  0.0001), dyslipidaemia (r  =  −0.31; 
P  =  0.028) and previous cardiovascular events 
(r = −0.37; P = 0.007) (see Fig. 2).
We subdivided patients with diabetes and diabetic foot 
regarding HbA1c (first tertile: HbA1c  <7%, second ter-
tile HbA1c >7%; third tertile HbA1c >10%. No significant 
correlation was observed among patients with diabetes 
without diabetic foot and diabetic patients with diabetic 
foot between HbA1C tertiles and PWV (P  =  0.104), 
RHI (P =  0.463), Aix (P =  0.294), whereas a significant 
negative correlation was observed between MMSE and 
HbA1C tertiles (R = 0.316; p = 0.037).
Discussion
In comparison to control diabetic subjects without dia-
betic foot and healthy controls we found that subjects 
with DFS had higher mean values of PWV, lower mean 
values of RHI and lower mean MMSE. To the best of 
our knowledge, only a few studies to date have evalu-
ated vascular health markers such as arterial stiffness 
and endothelial function indexes in diabetic foot sub-
jects compared to diabetic subjects without foot com-
plications and in healthy controls. Katakami et  al. [25] 
recently showed that evaluation of baPWV, in addition 
to carotid IMT and conventional risk factors, improved 
the ability to identify the diabetic individuals with high 
risk for CVE, whereas very recently Gomez-Marcos et al. 
[26] analyzed the relationship between cardio ankle vas-
cular index (CAVI), a new index of the overall stiffness, 
and target organ damage (TOD), vascular structure and 
function, and cardiovascular risk factors in Caucasian 
patients with type 2 diabetes mellitus or metabolic syn-
drome, suggesting that CAVI is positively associated with 
IMT, cf-PWV, ba-PWV, CAIx, and PAIx, regardless of 
cardiovascular risk and the drug treatment used.
Siasos et  al. [27] reported a significant association 
between diabetic microvascular complications such as 
diabetic retinopathy and vascular dysfunction, indicat-
ing that these conditions coexist in diabetic patients. 
In another study Antonopoulos et  al. reported [28] that 
both brachial FMD and AIx are strongly and indepen-
dently associated with DFS.
Nevertheless, to our knowledge no study has yet 
examined endothelial function by means of reactive 
hyperemia peripheral arterial tonometry (RH-PAT), 
thus our finding appears original. The main conse-
quence of endothelial dysfunction is the initiation of 
an inflammatory process which leads to the formation 
of atherosclerosis and its late sequel, cardiovascular 
morbidity and mortality. Because of its central role in 
mediating vessel tone and growth, its position as gate-
way to circulating immune cells, and its local regulation 
Table 2 Multinomial logistic regression analysis of  vari-
ables predictive of  diabetes and  diabetic foot presence 
Odds ratios (OR) were adjusted for drug therapy as covari-
ate
BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, 
Aortic AIx aortic augmentation index, AP augmentation pressure, PWV pulse 
wave velocity, RHI reactive hyperaemia index, MMSE mini mental state 
examination
Italic values indicate significance of p value (p < 0.05)
Variables OR 95% Confidence interval p
Diabetes
 Hypertension 3.68 0.96–14.03 0.056
 Dyslipidaemia 2.80 0.76–10.27 0.120
 Age 1.06 1.02–1.12 0.030
 BMI 1.21 1.07–1.36 0.002
 SBP 0.97 0.93–1.01 0.253
 Aix 1.0 0.96–1.04 0.887
 PWV 1.60 1.09–2.33 0.014
 RHI 0.31 0.10–0.96 0.043
 MMSE 0.17 0.35–0.89 0.036
Diabetic foot
 Hypertension 21.27 4.09–110.62 0.0001
 Dyslipidaemia 6.07 1.43–25.66 0.014
 Age 1.0 0.94–1.07 0.901
 BMI 1.17 1.02–1.34 0.019
 SBP 0.99 0.95–1.04 0.936
 AIx 1.01 0.90–1.14 0.757
 PWV 2.26 1.36–3.75 0.002
 RHI 0.01 0.001–0.185 0.002
 MMSE 0.27 0.04–1.79 0.176
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of hemostasis and coagulation, the properly function-
ing endothelium is the key to cardiovascular health. 
Diabetic foot syndrome is a micro and macrovascular 
complication of diabetes, and loss of this vasodilator 
mechanism may contribute to cardiovascular morbid-
ity such as disordered coronary flow regulation [29]. 
Furthermore, early stages of epicardial atherosclero-
sis are associated with an impairment in endothelium-
dependent dilation of the coronary microvasculature, 
indicating that the pathophysiological consequences of 
atherosclerosis may extend into the human coronary 
microcirculation [30].
Thus both microvascular and macrovascular complica-
tions of diabetes may be fully depicted by means of evalu-
ation of endothelium-dependent vasodilation indexes 
such as the PAT index RHI.
A previous study conducted by our group [12] reported 
that in comparison to diabetics without diabetic foot, 
Fig. 1 Area under ROC curve, sensitivity and specificity of PWV, Aix and RHI towards diabetes and diabetic foot (a–f). a Area under ROC curve, 
sensitivity and specificity of pulse wave velocity (PWV) in diabetic subjects vs. controls. b Area under ROC curve, sensitivity and specificity of ractive 
hyperaemia index (RHI) in diabetic subjects vs. controls c Area under ROC curve, sensitivity and specificity of pulse wave velocity (PWV) in subjects 
with diabetic foot vs. controls. d Area under ROC curve, sensitivity and specificity of ractive hyperaemia index (RHI) in subjects with diabetic foot 
vs. controls. e Area under ROC curve, sensitivity and specificity of pulse wave velocity (PWV) in subjects with diabetic foot vs. diabetics. f Area under 
ROC curve, sensitivity and specificity of ractive hyperaemia index (RHI in subjects with diabetic foot vs. diabetics
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subjects with diabetic foot had higher IL-6 and resitin 
plasma levels, and lower adiponectin plasma levels. These 
previous findings could represent a possible pathogenic 
explanation of higher arterial stiffness indexes and lower 
mean values of an endothelial function index such as the 
RHI reported by our current study.
Resistin contributes to insulin resistance and it may 
also regulate inflammatory responses [31]. Moreover, 
Osawa et  al. [32] reported that elevated serum resistin 
concentration appears to be an independent risk fac-
tor for ischemic stroke, especially lacunar and athero-
thrombotic infarction in the Japanese general population. 
The candidate role of hypo-adiponectinemia as a puta-
tive marker of cardiovascular morbidity may explain 
our findings of a higher degree of arterial stiffness and 
a low degree of endothelial function indexes in subjects 
with diabetic foot. Since adipose tissue produces sev-
eral cytokines [33], an “adipo-vascular” axis [34] may 
represent the pathogenic basis of the increased risk of 
cardiovascular events in patients with type 2 diabe-
tes, which is also well expressed by the involvement of 
surrogate cardiovascular markers such as arterial stiff-
ness and endothelial function indexes. In patients with 
diabetic foot lower plasma levels of adiponectin and 
higher plasma levels of IL-6 and resistin could be linked 
to endothelial dysfunction and progressive arterial stiff-
ening. Recent studies suggest that adiponectin may play a 
role in the modulation of inflammatory vascular response 
by inhibiting the expression of adhesion molecules on 
endothelial cells [35], inhibiting endothelial cell NF-kB 
signaling [36] and suppressing macrophage function [37]. 
Other studies showed that adiponectin suppressed the 
TNF-a-stimulated expression of E-selectin, VCAM-1 and 
ICAM-1 in human endothelial cells [38]. Adiponectin 
elicits mainly endothelium-dependent dilation of the ret-
inal arterioles [39]. Endothelium-dependent vasodilation 
likely induced by adiponectin results from NO via acti-
vation of guanylyl cyclase that is partially dependent on 
AMPK activity, thus low serum levels of adiponectin may 
explain our findings of a lower RHI index in subjects with 
diabetic foot. Our findings concerning significantly lower 
mean values of RHI and higher mean values of arterial 
Fig. 2 Significant correlations among clinical and arterial stiffness and endothelial function variables (a–c). a Correlation between PWV and RHI 
(reactive hyperaemia index); b correlation between RHI and hemoglobin A1c (HbA1c); c correlation between augmentation index (AIx) and hemo-
globin A1c; d correlation between minimental state examination (MMSE) score and age
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stiffness indexes may also contribute to explaining our 
findings of lower cognitive performance in subjects with 
diabetic foot.
Few studies have addressed the interplay between arte-
rial stiffness, type 2 diabetes, and cognitive performance. 
A recent study [40] reported that carotid stiffness is 
associated with cognitive performance in both individu-
als with and without diabetes, but does not mediate the 
relationship between type 2 diabetes and cognitive dys-
function. The role of primitive vascular alterations in 
the development of cognitive decline is a major issue in 
both research and clinical practice. In a recently pub-
lished cross-sectional study [29] conducted on the 
“ADELAHYDE” cohort comprised of older hypertensive 
patients with memory complaints showing the associa-
tion of arterial changes (hypertrophy and arterial stiff-
ness, endothelial dysfunction) with cognitive functions 
and/or white matter hyper intensities on MRI, the role 
of vascular factors in the evolution of cognitive function 
and onset of dementia has been confirmed.
Thus vascular abnormalities, independently of blood 
pressure levels, may play a role in the setting of subjec-
tive memory complaints as well as white matter hyper 
intensities (WMH) in elderly hypertensive patients. Arte-
rial thickness and stiffness as well as endothelial function 
should be assessed simultaneously and may represent 
additional targets for the prevention of subjective mem-
ory complaints and WMH. We have not reported mean 
MMSE values indicating clear cognitive dysfunction in 
both groups of diabetic subjects but our findings of lower 
MMSE mean scores observed in diabetic subjects with 
diabetic foot may represent a further issue confirming 
the role of arterial stiffness and endothelial dysfunction 
in the clinical setting of cognitive performance as well. 
Nevertheless our finding of an MMSE value of 26.5 ± 3.6 
in subjects with diabetic foot may suggest more impaired 
cognitive performance in subjects with a higher degree of 
arterial stiffness and a lower degree of endothelial medi-
ated vasodilation. Consistent with our findings a recent 
study [41] conducted to evaluate the utility of MMSE 
scores in detecting cognitive dysfunction in a sample of 
highly educated individuals showed that an MMSE cutoff 
score of 27 resulted in an optimal balance of sensitivity 
and specificity with an overall correct classification rate 
of 90% in a cognitively impaired group (dementia and 
MCI), thus indicating that a cutoff score of 27 might be 
more appropriate.
We previously reported [11] that diabetic patients with 
diabetic foot were more likely to have a higher preva-
lence of cardiovascular risk factors, a higher prevalence 
of previous cardiovascular morbidity (coronary artery 
disease, transient ischemic attack/ischemic stroke, dia-
betic retinopathy), and a higher prevalence of subclinical 
cardiovascular disease. Furthermore, diabetic patients 
with foot ulceration had a higher incidence of new-
onset vascular events (coronary artery disease, transient 
ischemic attack/ischemic stroke, diabetic retinopathy) on 
a 5-year follow-up.
Thus our findings of a significantly lower mean MMSE, 
consistent with our other findings concerning arterial 
stiffness and endothelial indexes in diabetic subjects with 
DFS could be related to the higher degree of cardiovas-
cular and cerebrovascular risk and more advanced cer-
ebral vascular disease both involving brain microvessels 
and brain white matter. The pathogenesis of cerebral 
small vessel disease, which involves white matter lesions 
(WMLs) and cerebral microbleeds (CMBs), is thought to 
be associated with endothelial dysfunction [42, 43].
In a mouse model of mice with genetically greater large 
artery stiffness a recent study [44] that examined the 
cause-and-effect relationship between large artery stiff-
ness and peripheral resistance artery function indicated 
the presence of an impaired cerebral artery endothe-
lial function. Another recent study [45] aimed to deter-
mine the associations between central hemodynamics 
and brain structure at rest and during exercise in people 
with and without T2DM, reporting that brain atrophy 
is associated with resting aortic stiffness in T2DM, and 
that central vascular mechanisms underlying structural 
brain changes may differ between healthy individuals 
and T2DM. These findings could also represent a further 
pathogenic issue of cognitive impairment in human sub-
jects with a higher degree of arterial stiffness.
Cognitive deficits in T2DM may also be partly attrib-
utable to stiffness in cerebral arteries and impaired vas-
odilator function, limiting the ability to increase blood 
flow in brain regions to meet cognitive demands. Nealon 
et al. [46] recently compared cerebrovascular responsive-
ness (CVR) and cognitive performance in adults with 
and without T2DM by means of measurements of basal 
cerebral mean blood flow velocity (MBFV) and pulsatil-
ity index (PI), a measure of arterial stiffness in the mid-
dle cerebral arteries (MCA) showing that PI was higher 
in the T2DM group with lower cognitive performance, 
and that cognitive function was inversely related to the 
PI/MBFV ratio, an indicator of intracranial stenosis.
Our findings on multinomial analysis concerning the 
predictive role of PWV, RHI and MMSE for diabetes 
presence, and PWV and RHI for diabetic foot presence 
are consistent with the higher degree of vascular impair-
ment of diabetic subjects and in particular diabetic sub-
jects with DFS. Arterial stiffness and endothelial function 
indexes are important surrogate markers that describe 
the capability of an artery to expand and contract in 
response to pressure changes and other stimuli. Thus a 
worse endothelial, arterial stiffness and cognitive profile 
Page 9 of 11Tuttolomondo et al. Cardiovasc Diabetol  (2017) 16:2 
of patients with diabetic foot could be a good marker of 
a higher degree of vascular involvement consistent with 
higher cardiovascular morbidity and metabolic cardio-
vascular pathogenic pathways of higher IL-6 and resis-
tin plasma levels, and lower adiponectin plasma levels as 
previously reported [12] in subjects with diabetic foot. 
Correlation analysis findings between arterial stiffness, 
endothelial function and cognitive markers and other 
clinical and laboratory variables help sketch the cardio-
vascular risk profile of subjects with diabetic foot. In sub-
jects with diabetic foot we observed a significant negative 
correlation between RHI values and previous cardiovas-
cular events, HBA1C and PWV, and a significant nega-
tive correlation between MMSE and age, dyslipidaemia 
and previous cardiovascular events. These findings high-
light the role of the cardiovascular and metabolic back-
ground of patients with diabetic foot in the pathogenesis 
of vascular and cognitive surrogate markers of vascular 
impairment, also suggesting a common mechanism of 
pathways for microvascular and macrovascular disease in 
diabetic subjects with foot complications.
Diabetes mellitus leads to accelerated progression of 
arteriosclerosis with an increased risk of coronary events 
in comparison to non-diabetic patients. A recent study 
[47] measured flow-mediated dilation (FMD) of the bra-
chial artery non-invasively as a marker for endothelial 
function, fractional diameter changes (FDC) as a marker 
for physical–mechanical properties, intima-media thick-
ness (IMT) as a marker for structural properties, and 
forearm blood flow (FBF) as a marker for microvascular 
function. This study reported that diabetes was associ-
ated with reduced FMD indicating impaired macrovas-
cular endothelial function and parallel reduced FDC 
and increased IMT, indicating increased stiffness and 
enhanced structural alterations and reduced forearm 
blood flow during reactive hyperemia indicating micro-
vascular dysfunction.
One common pathogenic mechanism for microvas-
cular disease is rooted in chemical reactions between 
by-products of sugars and proteins that occur over the 
course of days to weeks and eventually produce irre-
versible cross-linked protein derivatives called AGE [48] 
These derivatives can exhibit a wide range of effects on 
surrounding tissues, including modification (e.g. thicken-
ing) of collagen [49] and endothelium [50–53]. Neverthe-
less the pathogenesis of macrovascular disease in diabetes 
is multifactorial; the common recipient of injury is the 
vascular endothelium since diabetes initially impairs the 
ability of the vascular endothelium to vasodilate through 
inhibition of the nitric oxide [54]. The vascular endothe-
lium also loses its ability to produce NO-activated tis-
sue plasminogen activator, a fibrinolytic (anti-clotting) 
protein that inhibits the ability of inflammatory cells to 
“stick” to the endothelial surface [55, 56]. Insulin resist-
ance can also contribute to a decrease in NO production 
and the subsequent impaired vasodilatory response. In 
addition to the reduction in the vasodilatory response 
in diabetes, an overproduction of vasoconstriction sub-
stances occurs; these substances include endothelin 1, 
which has direct vasoconstrictive effects on the endothe-
lium as well as indirect fluid volume effects, including the 
stimulation of water and salt retention and the activation 
of the RAS. Both of these pathogenic pathways seem to 
be suggested by many of our findings, such as impaired 
arterial stiffness indexes and RHI indexes, and these ves-
sel changes may also explain the worse cognitive profile 
of subjects with diabetic foot in comparison to diabetic 
patients without foot complications and healthy subjects.
Limitations
We have not evaluated the prevalence of WMLs in our 
enrolled subjects thus avoiding an analysis of possible 
involvement of brain white matter disease in determining 
the lower cognitive performance of patients with diabetic 
foot. The cross-sectional analysis is a limitation since it 
does not allow conclusions on cause-effect relationships 
and the relatively small sample size may also limit con-
clusions. Nevertheless a future study conducted by our 
group will evaluate the prevalence of WMLs in subjects 
with diabetic foot in comparison to control subjects 
without diabetic foot.
Conclusions
This study reports that in comparison to controls, sub-
jects with diabetic foot had (1) higher mean levels of 
pulse wave velocity and augmentation index, and signifi-
cantly lower mean RHI values; (2) on multinomial logis-
tic regression analysis PWV and RHI were significantly 
predictive of diabetic foot diagnosis; (3) ROC curve 
analysis had good sensitivity and specificity of arterial 
stiffness and PAT indexes to predict diabetic foot; (4) 
on correlation analysis a significant negative correlation 
between PWV and RHI, RHI and previous cardiovascu-
lar events (HB1ac and between MMSE and age, dyslipi-
daemia, previous cardiovascular events). Future research 
could address these issues by means of longitudinal stud-
ies to evaluate cardiovascular event incidence in relation 
to arterial stiffness, endothelial and cognitive markers, 
and to address the beneficial effects of cardiovascular 
drugs such as statins and ACE inhibitors on these surro-
gate markers.
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